CN1333020A - 生化物质作为组合物用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病 - Google Patents

生化物质作为组合物用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病 Download PDF

Info

Publication number
CN1333020A
CN1333020A CN01124330A CN01124330A CN1333020A CN 1333020 A CN1333020 A CN 1333020A CN 01124330 A CN01124330 A CN 01124330A CN 01124330 A CN01124330 A CN 01124330A CN 1333020 A CN1333020 A CN 1333020A
Authority
CN
China
Prior art keywords
compositions
mcg
biochemical substances
magnesium
smooth muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN01124330A
Other languages
English (en)
Other versions
CN1245973C (zh
Inventor
马赛厄斯·拉思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1333020A publication Critical patent/CN1333020A/zh
Application granted granted Critical
Publication of CN1245973C publication Critical patent/CN1245973C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明涉及生化物质组合物用于预防和治疗由人体器官平滑肌收缩而引起的影响健康的疾病,所述疾病如高血压、哮喘、青光眼和耳鸣。

Description

生化物质作为组合物用于预防和治疗因人体器官 中平滑肌细胞收缩而引起的影响健康的疾病
技术领域
本发明总的来说涉及预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病。
发明背景
许多疾病的起因仍然是不清楚的。在这些不清楚起因的疾病中,最常见的疾病包括高血压、哮喘、青光眼和耳鸣。对于高血压来说,医学领域最有名的教科书之一“Harrison’s Principles of Internal Medicine”中描述了大约有90%患者的病因是不清楚的。世界范围内,数亿人患有这些影响健康的疾病并且因不能有效地治疗这些影响健康的疾病而对社会造成的经济损失是不可估量的。
世界范围内有数百万人患有支气管哮喘(哮喘)。在其后期阶段,哮喘是导致不能工作并与社会脱离的衰弱性疾病。这种疾病的起因仍然是不清楚的,即使已涉及到过敏源、遗传素因和心理学因素。该疾病的一般发病机理是肺中换气通道(支气管)梗阻而不能进入进行氧合作用的肺泡。然而,触发这种梗塞而引起哮喘的细胞机理仍然是不清楚的。
耳鸣是听力减弱的一种形式,大多数情况下是突然发生并且没有任何预兆。估计世界范围内有一百万以上的患者患有耳鸣和相关的听力减弱。这种疾病的起因和发病机理是不清楚的并且目前还没有改善耳鸣患者的听力的有效疗法。因此,许多这样的患者数年和数十年遭受听力受损并且对工作和社会生活能力常常产生有害的影响。
假定在不同器官中发生的各种明显不同的影响健康的疾病是因相同类型的细胞(称作平滑肌细胞)的生化机能障碍引起的。这种类型的肌细胞对有意识的控制不敏感,例如这与臂或腿的肌肉相反。所以,平滑肌细胞的合适代谢功能是在所有平滑肌细胞起重要功能的器官中避免使健康成问题的关键。
对于哮喘来说,假定可发现一般的细胞机制。细支气管和肺泡通道的壁包含一层平滑肌细胞。如果这些细胞收缩-与触发无关-这些肺管的直径会减小,导致换气量和氧合作用减少。因此,哮喘和/或梗塞性肺疾病患者的典型症状将发生。
对于耳鸣和听力减弱来说,可想得到的是听力减弱是由平滑肌细胞的痉挛引起的,平滑肌细胞形成使血液供应给内耳和介导听觉信号的神经细胞的血管内层。进一步假定耳毛细血管中这些平滑肌细胞的痉挛是由这些细胞最佳代谢功能必需的辅酶和其他生物能量分子的缺乏引起的。
在科学文献中没有发现对该概念的任何更早的描述。
对细胞的代谢和某些生化化合物在维持其合适功能的作用方面有了最新的进展。所以,纠正平滑肌细胞代谢的机能障碍是预防和治疗不同器官中各种影响健康的疾病的关键。
进一步发现细胞机能障碍可由某些需要在三羧酸循环(称作Krebs-循环)、呼吸链和平滑肌细胞其他代谢功能中用作辅酶的生化化合物的缺乏引起的。潜在的可预防和治疗的影响健康的疾病包括但不限于下列器官和疾病:
血管、肺、眼、尿-生殖道、胃肠道
高血压、心绞痛、耳鸣、阳萎、哮喘和其他形式的梗塞性肺疾病、青光眼和其他形式的眼压增加、月经前综合征、不孕症、输尿管和尿道痉挛、呃逆、胃痉挛、胆汁管痉挛。
发明概述
所以本发明的一个目的是给予患有包括但不限于上述影响健康疾病的患者一种生化物质组合物,所述生化物质由各种维生素、各种氨基酸和各种微量元素的化合物组成。
本发明的另一目的是给予患者生化物质组合物,组合物由至少一种选自抗坏血酸、可药用抗坏血酸盐和/或其混合物的抗坏血酸化合物组成。
本发明的另一目的是给予患者生化物质组合物,组合物由一种抗坏血酸化合物和至少一种选自精氨酸盐酸盐、可药用精氨酸盐和/或其混合物的精氨酸化合物组成。
本发明另一目的是给予患者生化物质组合物,组合物由抗坏血酸化合物、精氨酸化合物和至少一种选自镁或可药用镁盐和/或其混合物的镁化合物组成。
本发明的再一目的是给予患者下列生化物质的治疗组合物(不考虑这些加入成分的剂量):
抗坏血酸、棕榈酸抗坏血酸酯、β-,γ-,δ-生育酚混合物、β-胡萝卜素、生物素、抗坏血酸钙、柠檬酸钙、甘氨酸钙、类胡萝卜素混合物(α-类胡萝卜素(Alpha-Carot.)、叶黄素、zeea-、隐黄质)、胆钙化醇、甘氨酸铬、柑桔生物类黄酮、辅酶Q10、甘氨酸铜、氰钴胺素、d-α-生育酚、d-泛酸钙、磷酸二钙、叶酸、肌醇、L-精氨酸、L-肉碱、L-半胱氨酸、L-赖氨酸、L-脯氨酸、L-硒代蛋氨酸、抗坏血酸镁、柠檬酸镁、甘氨酸镁、锰螯合物、甘氨酸钼、烟酸、烟酰胺、钾螯合物、pycnogenol、pyrodoxine、核黄素、硫胺素、甘氨酸锌。
本发明的另一目的是给予患者生化物质组合物,而这些配方是以片剂、丸剂、注射剂、输注剂、吸入剂、栓剂或其他可药用载体和/或释放方式提供给患者的。
针对上述几种影响健康的疾病即高血压、哮喘和耳鸣进行这一构思的临床试验。
用这些生化物质组合物进行治疗导致至少部分平滑肌细胞明显松驰,导致大动脉(如,主动脉)动脉直径的增加而降低血压,增加中间大小动脉(如,冠状动脉)的动脉直径而使心绞痛减少,导致小动脉和毛细血管(如,耳动脉)直径的增加而改善听力,松驰肺细支气管和肺泡平滑肌细胞导致导气管直径增加而使哮喘症状减弱,松驰眼的导管系统导致如泪管直径的增加而减小眼压从而降低青光眼和视觉缺失的危险,松驰输卵管和子宫的平滑肌细胞导致肌组织松驰而改善生育力并减弱PMS症状,松驰胆管、输尿管和尿道的平滑肌细胞增加导管的直径而降低由胆结石或肾结石引起的痉挛危险。
已经公开了本发明的优选实施方案,仅以举例说明的方式提供下列实施例而不以任何方式限制本发明。
实施例
以该实施例所示物质的每日单位量给予患者下列生化物质的组合物:
生化物质     单位     量
抗坏血酸     mg     680
棕榈酸抗坏血酸酯     mg     620
β-,γ-,δ-生育酚混合物     mg     22
β-胡萝卜素     I.U.     1665
生物素     mcg     65
抗坏血酸钙     mg     1050
柠檬酸钙     mg     200
甘氨酸钙     mg     35
类胡萝卜素混合物(α-类胡萝卜素、叶黄素、zea-、隐黄质)     mcg     50
胆钙化醇     I.U.     130
甘氨酸铬     mcg     10
柑桔生物类黄酮     mg     650
辅酶Q10     mg     7
甘氨酸铜     mcg     330
氰钴胺素     mcg     20
d-α-生育酚     I.U.     230
d-泛酸钙     mg     40
磷酸二钙     mg     15
叶酸     mcg     90
肌醇     mg     35
L-精氨酸     mg     790
L-肉碱     mg     35
L-半胱氨酸     mg     35
L-赖氨酸     mg     110
L-脯氨酸     mg     110
L-硒代蛋氨酸     mcg     20
抗坏血酸镁     mg     1050
柠檬酸镁     mg     400
甘氨酸镁     mg     40
锰螯合物     mcg     1300
甘氨酸钼     mcg     4
烟酸     mg     10
烟酰胺     mg     35
钾螯合物     mg     20
pycnogenol     mg     7
pyrodoxine     mg     10
核黄素     mg     7
硫胺素     mg     7
甘氨酸锌     mg     7
mg=毫克mcg=微克I.U.=国际单位
然而,可改变该实施例生化物质组合物中的各个成分,不同于所使用的处方并且不考虑其量,只要80%以上成分与所述物质相同。而且,每日提供的各组分的量可不低于实施例所示量的10%并且不高于1000%。
本发明的构思在预期的临床研究中用8名哮喘患者来试验。这些患者按日剂量接受上表所列的生化化合物4个月。在该研究的开始和结束时,测量每个患者的肺体积。研究期间,哮喘患者的肺体积以超过20%的平均值增加。该研究的最有意义的结果是对于那些具有最低基线体积的患者来说,肺体积增加百分数高得多,这表明该治疗对于患有严重哮喘和严重呼吸损伤的患者来说是非常有价值的,显示在附图1中。
本发明的构思在预期的临床研究中用18名耳鸣患者以4个月的期限来试验。听力通过测听术来进行客观评价。测听术测量的前/后结果显示在附图2中。
证明:5名患者的听力很少或没有提高(0-10分贝[dB]),8名患者有提高10到20dB,两名患者在20到30dB之间,两名患者在30到40dB之间,并且一名患者听力提高40到50dB。
到现在为止,将组合物给予危及或患有至少部分由其身体器官平滑肌细胞收缩而引起的影响健康的疾病的患者是显而易见的。尽管公开了优选的实施方案和实施例,但可以理解本发明不以任何方式受此限制而是通过下文的权利要求及其等效物来定义的。

Claims (8)

1、生化物质组合物用于预防和治疗由人体器官平滑肌细胞收缩引起的影响健康的疾病,组合物由维生素、氨基酸和可药用微量元素组成。
2、生化物质组合物用于预防和治疗至少部分由人体器官平滑肌细胞收缩引起的影响健康的疾病,组合物由至少一种选自抗坏血酸、可药用抗坏血酸盐和/或其混合物的抗坏血酸化合物组成。
3、权利要求2的生化物质组合物的用途,组合物具有至少一种选自精氨酸盐酸盐、可药用精氨酸盐和/或其混合物的精氨酸化合物。
4、权利要求2和3的生化物质组合物的用途,组合物具有至少一种选自镁或可药用镁盐和/或其混合物的镁化合物。
5、上述权利要求生化物质组合物的用途,其中上述权利要求成分的组合是用下列一种或多种生化物质共同提供的并且不考虑这些加入成分的剂量: 生化物质     单位     量 抗坏血酸     mg     680 棕榈酸抗坏血酸酯     mg     620  β-,γ-,δ-生育酚混合物     mg     22 β-胡萝卜素     I.U.     1665 生物素     mcg     65 抗坏血酸钙     mg     1050 柠檬酸钙     mg     200 甘氨酸钙     mg     35 类胡萝卜素混合物(α-类胡萝卜素、叶黄素、zea-、隐黄质)     mcg     50 胆钙化醇     I.U.     130 甘氨酸铬     mcg     10 柑桔生物类黄酮     mg     650 辅酶Q10     mg     7 甘氨酸铜     mcg     330 氰钴胺素     mcg     20  d-α-生百酚     I.U.     230  d-泛酸钙     mg     40 磷酸二钙     mg     15 叶酸     mcg     90 肌醇     mg     35 L-精氨酸     mg     790 L-肉碱     mg     35 L-半胱氨酸     mg     35 L-赖氨酸     mg     110 L-脯氨酸     mg     110 L-硒代蛋氨酸     mcg     20 抗坏血酸镁     mg     1050 柠檬酸镁     mg     400 甘氨酸镁     mg     40 锰螯合物     mcg     1300 甘氨酸钼     mcg     4 烟酸     mg     10 烟酰胺     mg     35 钾螯合物     mg     20 pycnogenol     mg     7 pyrodoxine     mg     10 核黄素     mg     7 硫胺素     mg     7 甘氨酸锌     mg     7
mg=毫克mcg=微克I.U.=国际单位
6、上述权利要求的生化物质组合物的用途,其中所使用配方的各个成分有80%以上相同,不考虑它们的量。
7、上述权利要求的生化物质组合物的用途,其中每日所给的各个成分的量不低于权利要求5各个成分量的10%并且不高于1000%。
8、上述权利要求的生化物质组合物的用途,其中该配方是以片剂、丸剂、注射剂、输注剂、吸入剂、栓剂或其他可药用载体和/或释放方式提供给患者的。
CNB011243309A 2000-06-16 2001-06-15 生化物质在制备用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病的药物中的用途 Expired - Fee Related CN1245973C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00112811A EP1163904B1 (en) 2000-06-16 2000-06-16 Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium
EP00112811.5 2000-06-16

Publications (2)

Publication Number Publication Date
CN1333020A true CN1333020A (zh) 2002-01-30
CN1245973C CN1245973C (zh) 2006-03-22

Family

ID=8168995

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011243309A Expired - Fee Related CN1245973C (zh) 2000-06-16 2001-06-15 生化物质在制备用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病的药物中的用途

Country Status (23)

Country Link
EP (1) EP1163904B1 (zh)
JP (1) JP2002047183A (zh)
KR (1) KR100793573B1 (zh)
CN (1) CN1245973C (zh)
AT (1) ATE323479T1 (zh)
AU (1) AU780906C (zh)
BR (1) BR0103256A (zh)
CA (1) CA2350713C (zh)
CZ (1) CZ20012178A3 (zh)
DE (1) DE60027415T2 (zh)
DK (1) DK1163904T3 (zh)
ES (1) ES2258426T3 (zh)
HK (1) HK1043947A1 (zh)
HU (1) HUP0102489A2 (zh)
IL (1) IL143697A (zh)
NO (1) NO20013004L (zh)
PL (1) PL348097A1 (zh)
PT (1) PT1163904E (zh)
RU (1) RU2280441C2 (zh)
SK (1) SK285454B6 (zh)
TR (1) TR200101673A2 (zh)
UA (1) UA77147C2 (zh)
ZA (1) ZA200104931B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687204A (zh) * 2016-04-15 2016-06-22 石家庄东华金龙化工有限公司 一种甘氨酸金属螯合物复合物及其制备方法
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
CN108685754A (zh) * 2018-07-30 2018-10-23 郑州兰茜生物工程有限公司 一种用于耳鸣及具有健耳舒耳功能的滴耳剂

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163904B1 (en) * 2000-06-16 2006-04-19 Rath, Matthias, Dr. med. Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium
US6576634B1 (en) * 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
US6372264B1 (en) * 2000-08-24 2002-04-16 Gusty Winds Corporation Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
AU2001287917B2 (en) * 2000-09-22 2007-02-08 Mars Incorporated Food supplement
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
AU2003239154B2 (en) * 2002-01-31 2007-02-01 Chemstop Pty Ltd Process for the preparation of a nutrient formulation
AUPS019802A0 (en) * 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
GB0202900D0 (en) 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US20050238693A1 (en) * 2002-05-20 2005-10-27 Chemstop Pty Ltd. Process for the preparation and activation of susbstances and a means of producing same
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US9655966B2 (en) * 2002-08-28 2017-05-23 Kedar N. Prasad Micronutrient formulations for radiation applications
WO2004069822A1 (ja) * 2003-02-05 2004-08-19 Santen Pharmaceutical Co., Ltd. ステロイド副作用抑制組成物
WO2004073623A2 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
EP1628658A4 (en) * 2003-05-30 2007-09-05 Matthias Rath FUNCTIONAL COMPOSITION AND METHOD FOR INHIBITING CONTRACTION OF SMOOTH MUSCLE CELLS
WO2005094770A1 (en) * 2004-03-30 2005-10-13 Unilever Plc Skin lightening compositions comprising vitamines and flavonoids
FR2884691B1 (fr) * 2005-04-21 2007-07-20 Formquest Ltd Complement alimentaire comprenant une combinaison d'agents antioxydants et d'agents energisants utile comme aide a la fertilite chez l'homme et chez la femme
FR2884692B1 (fr) * 2005-04-21 2009-08-14 Formquest Ltd Complement alimentaire comprenant une association d'agents antioxydants et de carnitine, obtenue par synthese endogene ou exogene, comme aide a la fertilite chez l'homme et chez la femme
US7754700B2 (en) 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
EP1854453B1 (de) * 2006-05-12 2011-02-16 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG Lagerstabile wässrige Zusammensetzungen, umfassend eine Magnesiumverbindung und L-Carnitin
EP1862163A1 (de) * 2006-05-12 2007-12-05 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG L-Carnitin zur Kristallisationsverzögerung
RU2315612C1 (ru) * 2006-08-29 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Средство для лечения заболеваний глаз
WO2011033884A1 (ja) * 2009-09-18 2011-03-24 明治乳業株式会社 筋拘縮予防剤
AT510810B1 (de) * 2010-12-09 2017-09-15 Gonadosan Gmbh Kombinationspräparat zur verbesserung der weiblichen fertilität
JP2013049670A (ja) * 2011-08-04 2013-03-14 Fancl Corp アスコルビン酸製剤
WO2015199537A1 (en) * 2014-06-24 2015-12-30 Dedraf Holding B.V. New mineral composition
CN104688774A (zh) * 2015-02-17 2015-06-10 胡梨芳 包含手性异构化合物的赖氨酸磷酸氢钙药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
GB9922751D0 (en) * 1999-09-27 1999-11-24 Kenton Corp Limited A pharmaceutical composition for stabilising atherosclerotic plaques
EP1163904B1 (en) * 2000-06-16 2006-04-19 Rath, Matthias, Dr. med. Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687204A (zh) * 2016-04-15 2016-06-22 石家庄东华金龙化工有限公司 一种甘氨酸金属螯合物复合物及其制备方法
CN105687204B (zh) * 2016-04-15 2018-05-25 石家庄东华金龙化工有限公司 一种甘氨酸金属螯合物复合物及其制备方法
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
CN108685754A (zh) * 2018-07-30 2018-10-23 郑州兰茜生物工程有限公司 一种用于耳鸣及具有健耳舒耳功能的滴耳剂

Also Published As

Publication number Publication date
NO20013004D0 (no) 2001-06-15
DE60027415T2 (de) 2006-10-19
TR200101673A2 (tr) 2002-02-21
CN1245973C (zh) 2006-03-22
PL348097A1 (en) 2001-12-17
IL143697A0 (en) 2002-04-21
HUP0102489A2 (hu) 2003-11-28
KR100793573B1 (ko) 2008-01-14
ATE323479T1 (de) 2006-05-15
CA2350713A1 (en) 2001-12-16
ZA200104931B (en) 2001-12-20
CA2350713C (en) 2007-01-16
KR20010113499A (ko) 2001-12-28
BR0103256A (pt) 2002-03-12
SK8232001A3 (en) 2002-01-07
AU780906C (en) 2006-04-27
EP1163904B1 (en) 2006-04-19
HK1043947A1 (en) 2002-10-04
AU5194201A (en) 2001-12-20
CZ20012178A3 (cs) 2002-04-17
ES2258426T3 (es) 2006-09-01
UA77147C2 (en) 2006-11-15
NO20013004L (no) 2001-12-17
IL143697A (en) 2006-12-10
PT1163904E (pt) 2006-07-31
DE60027415D1 (de) 2006-05-24
RU2280441C2 (ru) 2006-07-27
SK285454B6 (sk) 2007-01-04
JP2002047183A (ja) 2002-02-12
DK1163904T3 (da) 2006-08-14
EP1163904A1 (en) 2001-12-19
AU780906B2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
CN1245973C (zh) 生化物质在制备用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病的药物中的用途
US6686340B2 (en) Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
Aversa et al. We are addicted to vitamins C and EA review
Lizardi-Cervera et al. Hepatic encephalopathy: a review
Robinson et al. Effects of nifedipine on resistance vessels, arteries and veins in man.
Ernst et al. Therapeutic interventions to lower plasma fibrinogen concentration
MXPA03002964A (es) Composiciones y metodos para reducir lipoproteina a de plasma y factores de riesgo de enfermedades cardiovasculares.
IE882740L (en) Preservative system for ophthalmic formulations
KR20070100721A (ko) 오르니틴 및 페닐아세테이트 또는 페닐부티레이트를 포함한간성 뇌병증 치료용 조성물
INGEMANSSON Clinical observations on ten cases of methanol poisoning with particular reference to ocular manifestations
Levin et al. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome
Aggarwal et al. Intravascular hemolysis in aluminium phosphide poisoning
Salahudeen et al. Cisplatin induces N-acetyl cysteine suppressible F2-isoprostane production and injury in renal tubular epithelial cells.
Schwaiblmair et al. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency–three-year follow-up
CN116173147B (zh) 芳香植物精油在制备治疗或预防高尿酸血症组合物中的应用
Teo et al. Effect of bile on vitamin B12 absorption.
Miyamoto et al. Present role of stereotactic thalamotomy for parkinsonism: retrospective analysis of operative results and thalamic lesions in computed tomograms
GB2600668A (en) Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection.
PT1060959E (pt) Composição para a prevenção de doenças do músculo liso, compreendendo ascorbato, argenina e magnésio
Zucconi et al. Sleep impairment by diethyldithiocarbamate in rat. Protective effects of pre-conditioning and antioxidants
Yuanwen et al. Unveiling the Deadly Effects of Hydrogen Cyanamide Poisoning: A Case Report
WO2023096617A1 (en) Use of aurantiamide acetate in the treatment of hypertension
Giuffrida Vascular Diseases and HBO
Fortunately Alpha-Lipoic Acid (Thioctic Acid): My Experience With This Outstanding Therapeutic Agent
US20060172951A1 (en) Age related macular degeneration and cutaneous signs of mercury toxicity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060322